Description

Buy Imfinzi (Durvalumab) For Sale USA

Durvalumab (Imfinzi) is used to treat non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), bile duct and gallbladder cancer, unresectable hepatocellular carcinoma and advanced or recurrent dMMR endometrial cancer, in certain patients. Durvalumab is a cancer immunotherapy used to help overall survival, lower the chance of cancer spreading, and help shrink tumors, depending on the type of cancer. Durvalumab works by helping the immune system find, recognize, and fight cancer cells.

Durvalumab is given as an infusion into a vein every 2, 3, or 4 weeks, depending on your condition. Other medicines may be part of your treatment plan, depending on your cancer type.

Durvalumab FDA approval (brand name Imfinzi)  was granted on May 1, 2017, for the company AstraZeneca, originally for Advanced Bladder Cancer, but FDA approval has since been extended for use in more cancer types.

How does durvalumab work?

Durvalumab class of medicines is called checkpoint inhibitors. Durvalumab works by binding and blocking the PD-L1 protein on the outside of cancer cells, which means your immune system can then find and attack the cancer cells to help slow cancer spreading and increase survival.

Durvalumab mechanism of action (MOA) is as a programmed death-ligand 1 (PD-L1) blocking antibody. It binds and blocks PD-L1, so there is no interaction with PD-1 and CD80. This means that the immune response is now activated to work against the cancer cells.

Durvalumab can be used for cancers that have a protein called PD-L1 on the outside of the cancer cell. The PD-L1 protein helps the cancer cells hide it from the immune system so cancer cells can survive and multiply. When durvalumab blocks PD-L1 it means the immune system is able to find cancers and destroy them.

What is durvalumab used for?

Durvalumab indications are non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer, hepatocellular carcinoma, and endometrial cancer in specific patients. Imfinzi is a prescripton medicine that is FDA-approved to treat adults with:

Non-small cell lung cancer (NSCLC)

• Non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements who have with resectable (tumors ≥ 4 cm and/or node positive). To be used in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinizi continued as a single agent as adjuvant treatment after surgery.
• Unresectable Stage III NSCLC in patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Imfinzi is to be used as a single agent.
• Metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. Imfinzi, Imjudo (tremelimumab-actl) and platinum-based chemotherapy are to be used in combination for the treatment regime.

Small cell lung cancer (SCLC)

• in combination with the chemotherapy medicines etoposide and carboplatin or cisplatin when cancer has spread within your lungs or to other parts of the body

• as a single agent, is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). Buy Imfinzi (Durvalumab) For Sale USA

Biliary tract cancer (including cancer of the bile ducts and gallbladder cancer) in combination with the chemotherapy medicines gemcitabine and cisplatin when cancer has spread to nearby tissues or other parts of the body

Durvalumab side effects

Common durvalumab side effects

Common durvalumab side effects include cough, rash, shortness of breath (dyspnea), tiredness (fatigue), cold symptoms (respiratory tract infections) inflammation of the lungs (pneumonitis), when used as a single agent for Stage III NSCLC.

When used with other cancer treatments, common durvalumab side effects may include nausea, constipation, decreased appetite, feeling weak or tired, bone or muscle pain, cough, feeling short of breath, cold symptoms such as stuffy nose, sneezing, sore throat, abdominal pain, fever, itchy skin, rash, painful urination, hair loss, vomiting, nerve inflammation (causing symptoms such as numbness, weakness, tingling, or burning), changes blood tests including decreased magnesium, increased ALT, and increased AST. Side effects profiles are dependent on the specific combination of therapies.

Immune-mediated hypothyroidism was reported in 14% of people receiving Imfinzi in combination with carboplatin and paclitaxel. Events resolved in some patients, but all required endocrine therapy.